Search results
Study finds LED therapy and antioxidant drug benefit muscle regeneration in Duchenne muscular ...
Medical Xpress· 1 day agoAs reported in an article published in the journal PLOS ONE, the strategy prevented muscle...
Pfizer Provides Update on Phase 3 Study of Investigational Gene Therapy for Ambulatory Boys with ...
Morningstar· 3 days ago(NYSE: PFE) today announced that CIFFREO, a Phase 3 global, multicenter, randomized, double-blind, placebo-controlled study evaluating the investigational mini-dystrophin gene therapy, fordadistrogene ...
Pfizer's Duchenne Muscular Dystrophy Treatment Misses Endpoints
Morningstar· 3 days agoPfizer's gene therapy being developed to treat Duchenne muscular dystrophy missed its primary endpoint in a late-stage trial. The pharmaceutical ...
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
Zacks via Yahoo Finance· 2 days agoPfizer’s PFE phase III study of investigational gene therapy, fordadistrogene movaparvovec, for...
Pfizer gene therapy for Duchenne fails to meet goals of key trial
BioPharma Dive via Yahoo Finance· 3 days agoThe negative results from the Phase 3 study, called Ciffreo, come a little more than a month after...
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test
Investor's Business Daily· 2 days agoSarepta stock jumped Thursday after Pfizer's rival gene therapy for Duchenne muscular dystrophy...
Bill headed to Pritzker's desk will screen babies for Duchenne muscular dystrophy
Chicago Sun-Times· 1 day agoMy wife and I could’ve never guessed a blood test would send our world crashing into a fatal...
Pfizer’s gene-therapy trial failure boosts Sarepta’s stock
Market Watch· 3 days agoPfizer Inc. said late Wednesday that its experimental gene therapy for Duchenne muscular dystrophy...
Pfizer setback brings questions for Duchenne gene therapy ahead of Sarepta decision
BioPharma Dive via Yahoo Finance· 3 days agoThe failure of another trial adds to uncertainty around the benefits of the gene-based treatments,...
Capricor Advances in DMD Therapy With Positive Study Data - Hims & Hers Health (NYSE:HIMS), Capricor...
Benzinga· 5 days agoThis contrasts sharply with the expected decline observed in untreated DMD patients, suggesting that...